Medeon Biodesign, Inc.
7F, 116, HouGang Street
Taipei
11170
Tel: 886-2-2881-6686
Fax: 886-2-2881-6907
Website: http://www.medeonbio.com/
Email: ir@medeonbio.com
About Medeon Biodesign, Inc.
Incepted in December 2012, Medeon Biodesign, an incubator group with focus on developing high value and high impact medical device products, is founded by the serial entrepreneur, Dr. Yue-Teh Jang, along with two prestigious healthcare institutional investors, Center Laboratories (TSE ticker: 4123), and Taiwan Global BioFund of YFY Group (TSE ticker: 1907). With headquarters based in Taipei, Taiwan and a US subsidiary located in Los Altos, California, together we bring in the integrated elements of skillful medical professionals, talented engineers, and international infrastructure, as the serving grounds for the innovative medtech platform we believe would thrive and shine.YEAR FOUNDED:
2012
LEADERSHIP:
General Manager: Dr. Yue-Teh Jang General Manager
Vice President: Dr. Yi-Ju Chen
VP of Research and Development: Dr. Shuling Cheng
VP of Operations: Ms. Elisa Huang
Senior Manager of Regulatory, Quality and Clinical Affairs: Ms. Greta Chang
Senior Manager of Business Development: Dr. Jenny Chen
7 articles about Medeon Biodesign, Inc.
-
Medeon Announces Positive Clinical Results for XFLO Minimally Invasive BPH Treatment Device
1/27/2021
Medeon Biodesign, Inc., a Taiwan publicly traded medical device company, is pleased to announce positive interim results of the EXPANDER-1 Clinical Study for its flagship product the XFLO™ Expander System, an innovative, minimally invasive Benign Prostatic Hyperplasia treatment solution.
-
Medeon Led and Completed Investments in Panther Orthopedics and Prodeon
7/8/2019
Medeon Biodesign, Inc., a Taiwan publicly traded medical device company, is pleased to announce that it recently led and closed two investments, in Panther Orthopedics and Prodeon.
-
Medeon Entering Asset Purchase Agreement with Terumo for its Large Bore Vascular Closure System
3/5/2018
Medeon Biodesign, Inc. is pleased to announce today that it entered into a definitive asset purchase agreement with Tokyo-based Terumo Corporation for its large bore vascular closure system.
-
Medeon Biodesign Announces Successful Clinical Use of AbClose Laparoscopic Port Site Closure Device in the United States
10/20/2017
Medeon Biodesign is pleased to announce that its innovative laparoscopic port site closure device, AbClose, successfully closed more than 50 wounds in a variety of laparoscopic surgeries.
-
Medeon Biodesign Announces Approval To Begin CE Clinical Study For The Xpro Large Bore Vascular Closure System
5/2/2017
-
Medeon Biodesign Announces Investing In Panther Orthorpedic For Orthopedic Extremity Applications
3/28/2017
-
Medeon Biodesign Wins FDA OK for Abclose - Laparoscopic Port Site Closure Device
9/19/2016